Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.88 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | HTR1D | P28221 | 1/20 | 0.59 |
| ▸ | HTR1B | P28222 | 1/20 | 0.59 |
| ▸ | HTR1E | P28566 | 1/20 | 0.59 |
| ▸ | HTR1F | P30939 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24878202 | 0.90 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL24877727 | 0.89 | HTR6 (0.79) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL24877683 | 0.89 | HTR6 (0.79) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL20307221 | 0.87 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL20307226 | 0.87 | HTR6 (0.78) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL2975416 | 0.85 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL24878095 | 0.84 | HTR6 (0.67) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL30808122 | 0.84 | HTR6 (0.70) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL30808124 | 0.84 | HTR6 (0.70) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL25330502 | 0.83 | HTR6 (0.73) | HTR6HTR1ADRD2HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954193-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2, BCL2L1 | HTR6 596/4885HTR1A 813/4885DRD2 3920/4885 |
| US-10954193-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2, BCL2L1 | HTR6 596/4885HTR1A 813/4885DRD2 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.